Varsha Walavalkar1, Egmond Evers2, Suresh Pujar1, Kiran Viralam1, Shreesha Maiya1, Stefan Frerich3, Colin John4, Shekhar Rao4, Chinnaswamy Reddy4, Bart Spronck5, Frits W Prinzen2, Tammo Delhaas6, Ward Y Vanagt7. 1. Department of Pediatric Cardiology, Narayana Institute of Cardiac Sciences, Bangalore, India. 2. Department of Physiology, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, Netherlands. 3. Department of Pediatric Cardiology, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, Netherlands. 4. Department of Pediatric Cardiac Surgery, Narayana Institute of Cardiac Sciences, Bangalore, India. 5. Department of Biomedical Engineering, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, Netherlands. 6. Department of Pediatric Cardiology, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, Netherlands Department of Biomedical Engineering, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, Netherlands. 7. Department of Physiology, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, Netherlands Department of Pediatric Cardiology, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, Netherlands ward.vanagt@maastrichtuniversity.nl.
Abstract
OBJECTIVES:Sildenafil has strong cardiac preconditioning properties in animal studies and has a safe side-effect profile in children. Therefore, we evaluated the application of Sildenafil preconditioning to reduce myocardial ischaemia/reperfusion injury in children undergoing surgical ventricular septal defect (VSD) closure. METHODS: This is a randomized, double-blind study. Children (1-17 years) undergoing VSD closure were randomized into three groups: placebo (Control group), preconditioning with 0.06 mg/kg (Sild-L group) and 0.6 mg/kg Sildenafil (Sild-H group). PRIMARY ENDPOINT: troponin release. CK-MB, Troponin I, inflammatory response (IL-6 and TNF-α), bypass and ventilation weaning times, inotropy score and echocardiographic function were assessed. Data expressed as median (range), and a value of P < 0.05 was considered significant. RESULTS:Thirty-nine patients were studied (13/group). Aortic cross-clamp time was similar [27 (18-85) and 27 (12-39) min] in the Control and Sild-L groups, respectively, but significantly longer [39 (20-96) min] in the Sild-H group when compared with the Control group. Area under the curve of CK-MB release was 1105 (620-1855) h ng/ml in the Control group, 1672 (564-2767) h ng/ml in the Sild-L group and was significantly higher in the Sild-H group [1695 (1252-3377) h ng/ml] when compared with the Control group. There were no significant differences in inflammatory response markers, cardiopulmonary bypass and ventilation weaning times, inotropy scores and echocardiographic function between the groups. CONCLUSIONS: In this small study, Sildenafil failed to reduce myocardial injury in children undergoing cardiac surgery, nor does it alter cardiac function, inotropic needs or postoperative course. A subclinical increase in cardiac enzyme release after Sildenafil preconditioning cannot be excluded. CLINICAL TRIALS REGISTRY: CTRI/2014/03/004468.
RCT Entities:
OBJECTIVES:Sildenafil has strong cardiac preconditioning properties in animal studies and has a safe side-effect profile in children. Therefore, we evaluated the application of Sildenafil preconditioning to reduce myocardial ischaemia/reperfusion injury in children undergoing surgical ventricular septal defect (VSD) closure. METHODS: This is a randomized, double-blind study. Children (1-17 years) undergoing VSD closure were randomized into three groups: placebo (Control group), preconditioning with 0.06 mg/kg (Sild-L group) and 0.6 mg/kg Sildenafil (Sild-H group). PRIMARY ENDPOINT: troponin release. CK-MB, Troponin I, inflammatory response (IL-6 and TNF-α), bypass and ventilation weaning times, inotropy score and echocardiographic function were assessed. Data expressed as median (range), and a value of P < 0.05 was considered significant. RESULTS: Thirty-nine patients were studied (13/group). Aortic cross-clamp time was similar [27 (18-85) and 27 (12-39) min] in the Control and Sild-L groups, respectively, but significantly longer [39 (20-96) min] in the Sild-H group when compared with the Control group. Area under the curve of CK-MB release was 1105 (620-1855) h ng/ml in the Control group, 1672 (564-2767) h ng/ml in the Sild-L group and was significantly higher in the Sild-H group [1695 (1252-3377) h ng/ml] when compared with the Control group. There were no significant differences in inflammatory response markers, cardiopulmonary bypass and ventilation weaning times, inotropy scores and echocardiographic function between the groups. CONCLUSIONS: In this small study, Sildenafil failed to reduce myocardial injury in children undergoing cardiac surgery, nor does it alter cardiac function, inotropic needs or postoperative course. A subclinical increase in cardiac enzyme release after Sildenafil preconditioning cannot be excluded. CLINICAL TRIALS REGISTRY: CTRI/2014/03/004468.